Last Week in Biomedicine | June 14–20 | Part 1 of 2: CRISPR HAE Cure, Narcolepsy Orexin Breakthrough

Last Week in Biomedicine | June 14–20 | Part 1 of 2: CRISPR HAE Cure, Narcolepsy Orexin Breakthrough

This week opened with one of the most significant gene-editing milestones in clinical medicine: a single CRISPR infusion cut hereditary angioedema attacks by 87 percent in a Phase 3 trial, published the same day in the New England Journal of Medicine. Plus a first-in-class drug that may reshape how we treat narcolepsy, and the first new oral antifungal class in over 20 years.

In Part 1 we cover:

1. Intellia Therapeutics — Lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (Phase 3)

2. Takeda Pharmaceutical — Oveporexton (TAK-861) for narcolepsy type 1 (Phase 3)

3. F2G / Shionogi — Olorofim for invasive aspergillosis (Phase 3)


The Intellia readout is the headline of the week. Hereditary angioedema causes sudden, painful and sometimes life-threatening swelling attacks, and current treatments require regular injections to suppress them. Lonvo-z is given once — a tiny package of CRISPR machinery shuts down the gene responsible for the attacks inside liver cells permanently — and 81 percent of patients were completely attack-free at one year. If this holds up, an entire category of chronic disease management could be replaced by single-dose curative gene

editing.


Part 2 drops Thursday morning. Subscribe at TrialBreaks.com.


#biomedicine #clinicaltrials #science #CRISPR #genetherapy #raredisease

#neurology #narcolepsy #orexin #infectiousdisease #antifungal #immunology #HAE

#aspergillosis #drugdevelopment


Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(13)

Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hyper...

25 Juni 25min

Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary

Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary

Part 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in psoriasis, and Agios's...

18 Juni 21min

Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill

Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill

A blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill cleared two Phase 3 trials. ...

16 Juni 20min

Last Week in Biomedicine | May 30 – Jun 5 | Part 2 of 2: Talzenna Prostate Combo, IgG4 Disease First

Last Week in Biomedicine | May 30 – Jun 5 | Part 2 of 2: Talzenna Prostate Combo, IgG4 Disease First

From a prostate cancer combo that uses your tumor's own broken DNA-repair against it, to the first drug ever to succeed in a rare autoimmune disease called IgG4-related disease — Part 2 of our weekly ...

11 Juni 16min

Last Week in Biomedicine | May 30 – Jun 5 | Part 1 of 2: Daraxonrasib Pancreatic Cancer, Ivonescimab Lung

Last Week in Biomedicine | May 30 – Jun 5 | Part 1 of 2: Daraxonrasib Pancreatic Cancer, Ivonescimab Lung

The biggest week in cancer research of 2026 dropped at the ASCO meeting in Chicago, and one drug stole the show: a new RAS-blocking pill that nearly doubled survival in metastatic pancreatic cancer, o...

9 Juni 20min

Last Week in Biomedicine | May 23–29 | Part 2 of 2: Apogee Eczema, TG Therapeutics MS

Last Week in Biomedicine | May 23–29 | Part 2 of 2: Apogee Eczema, TG Therapeutics MS

In Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience win.4. Apogee Therapeu...

4 Juni 11min

Last Week in Biomedicine | May 23–29 | Part 1 of 2: BMS Myeloma, GSK Hep B Cure, Pfizer Lung Cancer

Last Week in Biomedicine | May 23–29 | Part 1 of 2: BMS Myeloma, GSK Hep B Cure, Pfizer Lung Cancer

In Part 1 we cover the three biggest clinical trial readouts from the week of May 23–29, 2026 — including two ASCO 2026 opening-day announcements that reshape oncology.1. Bristol Myers Squibb — Mezigd...

2 Juni 36min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
inga-beiga-morsor
rss-vuxna-pa-latsas
sexnoveller-deluxe
not-fanny-anymore
sova-med-dan-horning
rss-viktmedicinpodden
johannes-hansen-podcast
angestpodden
rss-pappahjartat
tyngre-radio
sa-in-i-sjalen
brottarbroder
rss-basta-livet
rss-hos-psykologen
sex-pa-riktigt-med-marika-smith
medicinvetarna
rss-traningsklubben
rss-activation-podcast